A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT, WITHOUT TYPE 2 DIABETES (ENLIGHTEN-1)

Registry ID
J3R-MC-YDAG
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE3
Study type
INTERVENTIONAL
Sponsor
ELI LILLY CANADA INC
Start date
2026-03-31
Last update
2026-02-24

Conditions

Related clinical trials

View on source registry